Trials / Completed
CompletedNCT01676688
Safety Study of Alfalastin (Human Alpha-1 Antitrypsin) Administered at Home
Safety Study of Alfalastin (Human Alpha-1 Antitrypsin, 33.33 mg/ml) Administered at Home to Patients Suffering From Severe Forms of Primary Deficiency in Alpha-1 Antitrypsin, Phenotype PIZZ or PISZ, With Pulmonary Emphysema.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 17 (actual)
- Sponsor
- Laboratoire français de Fractionnement et de Biotechnologies · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to collect safety data on ALFALASTIN® infusions performed at home or in out-of hospital locations.
Detailed description
Non interventional, observational, longitudinal, prospective, multicenter, non comparative study.
Conditions
Timeline
- Start date
- 2012-01-01
- Primary completion
- 2012-09-01
- Completion
- 2012-10-01
- First posted
- 2012-08-31
- Last updated
- 2023-10-03
Source: ClinicalTrials.gov record NCT01676688. Inclusion in this directory is not an endorsement.